Table 96-1. Mediastinal Seminoma: Treatment with Cisplatin-Based Combination Chemotherapy

Table 96-1.  Mediastinal Seminoma: Treatment with Cisplatin-Based Combination Chemotherapy

Author, Year	Number of Patients	Received Previous Radiotherapy	Treatment Regimen	Number of Complete Responses (%)	Number of Long-Term Disease-Free Survivors (months)
Hainsworth, 198232	4	3	PVB	3 ( 75%)	3 (> 24 months)
Jain, 198428	11	0	VAB-6, 8, PVB 1, DDP/CTX 2	10 ( 91%)	10 (19 + -46 months)
Logothetis, 198534	4	Unspecified	DDP/CTX 3, CISCA21	4 (100%)	4 (unspecified)
Loehrer, 198763	9	7	PVB ± A or BEP	8 ( 89%)	7 (unspecified)
Bukowski, 199364	8	0	PVB/EBAP	5 ( 63%)	4 (> 24 months)
Delgado, 199365	6	0	VAP-6, PVB, BEP	5 ( 83%)	5 (5-103 months)
Goss, 199466	8	0	BEP 6, BEP + RT 1, VAB-6 1	8 (100%)	8 (4-132 months)
Mencel, 199467	19	0	VAP-6, EP	19 (100%)	19 (> 24 months)
Gerl, 199668	4	1	VIOP, EIP	4 (100%)	4 (> 24 months)
Bokemeyer, 200169	51	0	Cisplatin-based	NA	45 (88%)

A = Adriamycin; BEP = bleomycin 30 U weekly, etoposide 100 mg/m² IV × 5 days, cisplatin 20 mg/m² IV × 5 days, cycles repeated q 3 weeks; CISCA2 = multidrug regimen developed at M.D. Anderson; CTX = cyclophosphamide; DDP = cisplatin; EBAP = etoposide, bleomycin, cisplatin; PVB (Einhorn regimen) = cisplatin 20 mg/m² IV × 5 days, vinblastine 0.15 mg/kg D 1,2, bleomycin 30 U weekly, cycle repeated q 3 weeks; VAB-6 = multidrug regimen developed at Sloan-Kettering.